Antimicrobial Stewardship

Infectious Disease Clinics of North America

Volumn 25, Issue 1, 2011, Pages 245-260

  Tamma, Pranita D ^a   Cosgrove, Sara E ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Antibiotic management; Antimicrobial stewardship; Formulary restriction

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CASPOFUNGIN; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; METICILLIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTEREMIA; BACTERIAL INFECTION; BACTERIAL MENINGITIS; CANDIDEMIA; CLINICAL LABORATORY; CLINICAL PHARMACY; CLOSTRIDIUM DIFFICILE INFECTION; COMPUTER ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DECISION SUPPORT SYSTEM; DRUG COST; DRUG EFFICACY; DRUG MONITORING; DRUG TREATMENT FAILURE; DRUG USE; GRAM NEGATIVE INFECTION; HEALTH EDUCATION; HEALTH PROGRAM; HOSPITAL INFECTION; HOSPITAL MANAGEMENT; HUMAN; INFECTION CONTROL; INFORMATION TECHNOLOGY; KLEBSIELLA INFECTION; MEDICAL CARE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MICROBIOLOGY; NONHUMAN; PATIENT SAFETY; PHARMACY AND THERAPEUTICS COMMITTEE; PRESCRIPTION; PROGRAM DEVELOPMENT; PUBLIC HEALTH SERVICE; REVIEW; TREATMENT RESPONSE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG UTILIZATION; DRUG UTILIZATION REVIEW; GUIDELINE ADHERENCE; HUMANS; INFECTION CONTROL; PRACTICE GUIDELINES AS TOPIC; PROGRAM DEVELOPMENT;

EID: 79551714338     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.idc.2010.11.011     Document Type: Review

References (64)

1. Spellberg B., Powers J.H., Brass E.P., et al. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004, 38:1279-1286.
2. Tenover F.C., Hughes J.M. The challenges of emerging infectious diseases. Development and spread of multiply-resistant bacterial pathogens. JAMA 1996, 275(4):300-304.
3. Davey P., Brown E., Fenelon L., et al. Interventions to improve antibiotic prescribing practices for hospital inpatients. The Cochrane Library 2005, 4:1-117.
4. Dellit T.H., Owens R.C., McGowan J.E., et al. Infectious Disease Society of American and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial susceptibility. Clin Infect Dis 2007, 44:159-177.
5. Reimann H.A., D'Ambola J. The use and cost of antimicrobials in hospitals. Arch Environ Health 1966, 13:631-636.
6. Office of Technology Assessment USC Impacts of antibiotic-resistant bacteria. OTA-H-629 1995, Government Printing Office, Washington, DC.
7. Schentag J.J., Ballow C.H., Fritz A.L., et al. Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory. Diagn Microbiol Infect Dis 1993, 16:255-264.
8. Carling P., Fung T., Killion A., et al. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol 2003, 24:699-706.
9. LaRocco A. Concurrent antibiotic review programs-a role for infectious diseases specialists at small community hospitals. Clin Infect Dis 2003, 37:742-743.
10. Ansari F., Gray K., Nathwani D., et al. Outcomes of an intervention to improve hospital antibiotic prescribing: interrupted time series with segmented regression analysis. J Antimicrob Chemother 2003, 52:842-848.
11. Ruttimann S., Keck B., Hartmeier C., et al. Long-term antibiotic cost savings from a comprehensive intervention program in a medical department of a university-affiliated hospital. Clin Infect Dis 2004, 38:348-356.
12. Lutters M., Harbarth S., Janssens J.P., et al. Effect of a comprehensive, multidisciplinary, educational program on the use of antibiotics in a geriatric university hospital. J Am Geriatr Soc 2004, 52:112-116.
13. Scheckler W.E., Bennett J.V. Antibiotic usage in seven community hospitals. JAMA 1970, 213(2):264-267.
14. MacDougall C., Polk R.E. Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev 2005, 18(4):638-656.
15. Kisuule F., Wright S., Barreto J., et al. Improving antibiotic utilization among hospitalists: a pilot academic detailing project with a public health approach. J Hosp Med 2007, 10:93-101.
16. Gross R., Morgan A.S., Kinky D.E., et al. Impact of a hospital-based antimicrobial management program on clinical and economic outcomes. Clin Infect Dis 2001, 33:289-295.
17. MacLaren R., Devlin J.W., Martin S.J., et al. Critical care pharmacy services in United States hospitals. Ann Pharmacother 2006, 40:612-618.
18. Steffee C.H., Morrell R.M., Wasilauskas B.L. Clinical use of rifampicin during routine reporting of rifampicin susceptibilities: a lesson in selective reporting of antimicrobial susceptibility data. J Antimicrob Chemother 1997, 40:595-598.
19. Forrest G.N., Mehta S., Weekes E., et al. Impact of rapid in situ hybridization testing on coagulase-negative staphylococci positive blood cultures. J Antimicrob Chemother 2006, 58:154-158.
20. Forrest G.N., Mankes K., Jabra-Rizk A., et al. Peptide nucleic acid fluorescence in situ hybridization-based identification of Candida albicans and its impact on mortality and antifungal therapy costs. J Clin Microbiol 2006, 44(9):3381-3383.
21. Forrest G.N., Roghmann M., Toombs L.S., et al. Peptide nucleic acid fluorescent in situ hybridization for hospital-acquired enterococcal bacteremia: delivering earlier effective antimicrobial therapy. Antimicrob Agents Chemother 2008, 52(10):3558-3563.
22. Goldmann D.A., Weinstein R.A., Wenzel R.P., et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals: a challenge to hospital leadership. JAMA 1996, 275(3):234-240.
23. Paskovaty A., Pflomm J.M., Myke N., et al. A multidisciplinary approach to antimicrobial stewardship: evolution into the 21st century. Int J Antimicrob Agents 2005, 25:1-10.
24. Safdar N., Maki D.G. The commonality of risk factors for nosocomial colonization and infection with antimicrobial-resistant Staphylococcus aureus, enterococcus, gram-negative bacilli, Clostridium difficile, and Candida. Ann Intern Med 2002, 136:834-844.
25. Monnet D.L. Methicillin-resistant Staphylococcus aureus and its relationship to antimicrobial use: possible implications for control. Infect Control Hosp Epidemiol 1998, 19:552-559.
26. Mol P.G., Rutten W.J., Gans R.O., et al. Adherence barriers to antimicrobial treatment guidelines in teaching hospitals, The Netherlands. Emerg Infect Dis 2004, 10(3):522-525.
27. Price J., Ekleberry A., Grover A., et al. Evaluation of clinical practice guidelines on outcome of infection in patients in the surgical intensive care unit. Crit Care Med 1999, 27(10):2118-2124.
28. Singh N., Rogers P., Atwood C.W., et al. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. Am J Respir Crit Care Med 2000, 162:505-511.
29. Bantar C., Sartori B., Vesco E., et al. A hospitalwide intervention program to optimize the quality of antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance. Clin Infect Dis 2003, 37:180-186.
30. Belongia E.A., Knobloch M.J., Kieke B.A., et al. Impact of statewide program to promote appropriate antimicrobial drug use. Emerg Infect Dis 2005, 11(6):912-920.
31. Coleman R.W., Rodondi L.C., Kaubisch S., et al. Cost-effectiveness of prospective and continuous parenteral antibiotic control: experience at the Palo Alto Veterans Affairs Medical Center from 1987 to 1989. Am J Med 1991, 90:439-444.
32. Seligman S.J. Reduction in antibiotic costs by restricting use of an oral cephalosporin. Am J Med 1981, 71:941-944.
33. Britton H.L., Schwinghammer T.L., Romano M.J. Cost containment through restriction of cephalosporins. Am J Hosp Pharm 1981, 38(12):1897-1900.
34. Hayman J.N., Sbravati E.C. Controlling cephalosporins and aminoglycoside costs through pharmacy and therapeutics committee restrictions. Am J Hosp Pharm 1985, 42(6):1343-1347.
35. Woodward R.S., Medoff G., Smith M.D., et al. Antibiotic cost savings from formulary restrictions and physician monitoring in a medical-school-affiliated hospital. Am J Med 1987, 83:817-823.
36. Maswoswe J.J., Okpara A.U. Enforcing a policy for restricting antimicrobial use. Am J Health Syst Pharm 1995, 52(13):1433-1435.
37. White A.C., Atmar R.L., Wilson J., et al. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997, 25:230-239.
38. Frank M.O., Batteiger B.E., Sorensen S.J., et al. Decrease in expenditures and selected nosocomial infections following implementation of an antimicrobial-prescribing improvement program. Clin Perform Qual Health Care 1997, 5(4):180-188.
39. Rahal J.J., Urban C., Horn D., et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998, 280(14):1233-1237.
40. Agwu A.L., Lee C.K., Jain S.K., et al. A world wide web-based antimicrobial stewardship program improves efficiency, communication, and user satisfaction and reduces cost in a tertiary care pediatric medical center. Clin Infect Dis 2008, 47:747-753.
41. Cosgrove S.E., Patel A., Song X., et al. Impact of different methods of feedback to clinicians after post prescription antimicrobial review based on the Centers for Disease Control and Prevention's 12 steps to prevent antimicrobial resistance among hospitalized adults. Infect Control Hosp Epidemiol 2007, 28:641-646.
42. Grimshaw J.M., Shirran L., Thomas R., et al. Changing provider behavior: an overview of systematic reviews of interventions. Med Care 2001, 39:112-145.
43. Solomon D.H., Van Houten L., Glynn R.J. Academic detailing to improve use of broad-spectrum antibiotics at an academic medical center. Arch Intern Med 2001, 161:1897-1902.
44. Gums J.G., Yancey R.W., Hamilton C.A., et al. A randomized, prospective study measuring outcomes after antibiotic therapy intervention by a multidisciplinary consult team. Pharmacotherapy 1999, 19(12):1369-1377.
45. Connor D.M., Binkley S., Fishman N.O., et al. Impact of automatic orders to discontinue vancomycin therapy on vancomycin use in an antimicrobial stewardship program. Infect Control Hosp Epidemiol 2007, 28(12):1408-1410.
46. Glowacki R.C., Schwartz D.N., Itokazu G.S., et al. Antibiotic combinations with redundant antimicrobial spectra: clinical epidemiology and pilot intervention of computer-assisted surveillance. Clin Infect Dis 2003, 37:59-64.
47. Evans R.S., Pestotnik S.L., Classen D.C., et al. Evaluation of a computer-assisted antibiotic-dose monitor. Ann Pharmacother 1999, 33:1026-1031.
48. Evans R.S., Pestotnik S.L., Classen D.C., et al. A computer-assisted management program for antibiotics and other antiinfectives agents. N Engl J Med 1998, 338:232-238.
49. Pestotnik S.L., Classen D.L., Evans R.S., et al. Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. Ann Intern Med 1996, 124:884-890.
50. Fishman N. Antimicrobial stewardship. Am J Infect Control 2006, 34:S65-S73.
51. Fridkin S.K. Routine cycling of antimicrobial agents as an infection-control measure. Clin Infect Dis 2003, 36:1438-1444.
52. Raymond D.P., Pelletier S.J., Crabtree T.D., et al. Impact of a rotating empiric schedule on infectious mortality in an intensive care unit. Crit Care Med 2001, 29(6):1101-1108.
53. Van Loon H.J., Vriens M.R., Fluit A.C., et al. Antibiotic rotation and development of Gram-negative antibiotic resistance. Am J Respir Crit Care Med 2005, 171:480-487.
54. Bonhoeffer S., Lipsitch M., Levin B.R. Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci U S A 1997, 94:12106-12111.
55. Bergstrom C.T., Lo M., Lipsitch M. Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc Natl Acad Sci U S A 2004, 7:13101-13102.
56. Brown E.M., Nathwani D. Antibiotic cycling or rotation: a systematic review of the evidence of efficacy. J Antimicrob Chemother 2005, 55:6-9.
57. Metlay J.P., Shea J.A., Crossette L.B., et al. Tensions in antibiotic prescribing: pitting social concerns against interests of individual patients. J Gen Intern Med 2002, 17:87-94.
58. Sunenshine R.H., Kiedkte L.A., Jernigan D.B., et al. Role of infectious diseases consultants in management of antimicrobial use in hospitals. Clin Infect Dis 2004, 38:934-938.
59. Soumerai S.B., Avorn J. Principles of educational outreach ('academic detailing') to improve clinical decision making. JAMA 1990, 263(4):549-556.
60. Pritchard V. Joint Commission standards for long-term care infection control: putting together the process elements. Am J Infect Control 1999, 27:27-34.
61. The Joint Commission Available at:, Accessed February 10, 2010. http://www.jcrinc.com/2009-NPSGs-Goal-7/.
62. Perencevich E.N., Stone P.W., Wright S.B., et al. Raising standards while watching the bottom line: making a business case for infection control. Infect Control Hosp Epidemiol 2007, 28(10):1121-1133.
63. Polk R.E., Fox C., Mahoney A., et al. Measurement of adult antibacterial drug use in 130 US hospitals: comparison of defined daily dose and days of therapy. Clin Infect Dis 2007, 44(5):664-670.
64. Pakyz A.L., MacDougall C., Oinonen M., et al. Trends in antibacterial use in US health centers. Arch Intern Med 2008, 168(20):2254-2260.